JP3 enhances the toxicity of cisplatin on drug-resistant gastric cancer cells while reducing the damage to normal cells

Background: Cisplatin (DDP) is a highly effective chemotherapeutic agent to most solid tumors including gastric cancer (GC), however, its clinical value is limited due to severe toxic side effects and secondary drug resistance. JP3, a JWA protein based MMP2-targeted polypeptide, known to inhibit the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yi, Chen, Junjie, Che, Zhen, Shu, Chuanjun, Chen, Dongyin, Ding, Kun, Li, Aiping, Zhou, Jianwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7974513/
https://www.ncbi.nlm.nih.gov/pubmed/33753987
http://dx.doi.org/10.7150/jca.50306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7974513/
https://www.ncbi.nlm.nih.gov/pubmed/33753987
http://dx.doi.org/10.7150/jca.50306

Ejemplares similares